SHANGHAI, Dec. 23, 2025 /PRNewswire/ — Xiao-I Corporation (NASDAQ: AIXI) (the “Company”) today announced that it has received two written notifications from theSHANGHAI, Dec. 23, 2025 /PRNewswire/ — Xiao-I Corporation (NASDAQ: AIXI) (the “Company”) today announced that it has received two written notifications from the

Xiao-I Corporation Announces Receipt of Nasdaq Listing Deficiency Notices

SHANGHAI, Dec. 23, 2025 /PRNewswire/ — Xiao-I Corporation (NASDAQ: AIXI) (the “Company”) today announced that it has received two written notifications from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with certain continued listing requirements for The Nasdaq Global Market.

Minimum Bid Price Deficiency

On December 16, 2025, the Company received a notice from Nasdaq stating that the Company does not currently satisfy the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1), which requires a minimum closing bid price of $1.00 per share.

The notice was based on the Company’s American Depositary Shares having a closing bid price below $1.00 per share for 30 consecutive business days from November 3, 2025 through December 15, 2025. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided a 180-calendar-day compliance period, expiring on June 16, 2026, to regain compliance. If at any time during this period the closing bid price of the Company’s securities is at least $1.00 per share for a minimum of ten consecutive business days, Nasdaq will provide written confirmation that the Company has regained compliance.

Market Value of Publicly Held Shares Deficiency

On December 17, 2025, the Company received a second notice from Nasdaq stating that the Company does not currently satisfy the minimum Market Value of Publicly Held Shares (“MVPHS”) requirement set forth in Nasdaq Listing Rule 5450(b)(3)(C), which requires MVPHS of at least $15.0 million.

Nasdaq determined that, based on the Company’s MVPHS for 30 consecutive business days from November 4, 2025 through December 16, 2025, the Company no longer met this requirement. In accordance with Nasdaq Listing Rule 5810(c)(3)(D), the Company has been provided a 180-calendar-day compliance period, expiring on June 15, 2026, to regain compliance. If during this period the Company’s MVPHS closes at $15.0 million or more for a minimum of ten consecutive business days, Nasdaq will confirm that the Company has regained compliance.

Status and Next Steps

The Nasdaq notices have no immediate effect on the listing or trading of the Company’s American Depositary Shares on The Nasdaq Global Market. The Company intends to assess its current compliance status and develop and evaluate potential plans to regain compliance with the applicable Nasdaq listing requirements within the prescribed compliance periods. While there can be no assurance that the Company will be able to regain compliance with either listing requirement or that Nasdaq will grant any additional compliance periods, the Company believes it has a range of potential options available and remains committed to working diligently toward regaining compliance.

Cision View original content:https://www.prnewswire.com/news-releases/xiao-i-corporation-announces-receipt-of-nasdaq-listing-deficiency-notices-302648773.html

SOURCE Xiao-I Corporation

Market Opportunity
Notcoin Logo
Notcoin Price(NOT)
$0.0005151
$0.0005151$0.0005151
+1.87%
USD
Notcoin (NOT) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.